My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Alogliptin (SYR-322)
    Alogliptin (SYR-322)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0745
    CAS #: 850649-61-5Purity ≥98%

    Description: Alogliptin (also known as SYR-322) is a novel, potent, orally bioavailable, and selective inhibitor of DPP-4 (serine protease dipeptidyl peptidase IV) with IC50 value of 2.6 nM, it exhibits greater than 10,000-fold selectivity for DPP-4 over the closely related DPP-8 and DPP-9. It is an anti-diabetic drug marketed in Japan since 2010; and in 2013, the FDA approved the drug in three formulations: as a stand-alone with the brand-name Nesina, combined with metformin using the name Kazano, and when combined with pioglitazone as Oseni. Like other medications for the treatment of Type 2 diabetes, alogliptin does not decrease the risk of heart attack and stroke. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone. 

    References: J Med Chem. 2007 May 17;50(10):2297-300; Life Sci. 2009 Jul 17;85(3-4):122-6.

    Related CAS: 850649-62-6 (benzoate); 1246817-18-4 [Alogliptin (13CD3]

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Citation of InvivoChem venetoclax and S63845
    • Citation of InvivoChem KD025 (SLx-2119)
    • Citation of InvivoChem Tubastatin A HCl
    • Citation of InvivoChem BMS-1166
    • Citation of InvivoChem Paclitaxel
    • Citation of InvivoChem Colchicine
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)339.39
    FormulaC18H21N5O2
    CAS No.850649-61-5 (free base);
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 68 mg/mL (200.4 mM)
    Water: 2 mg/mL (5.89 mM) 
    Ethanol:<1 mg/mL
    Solubility (In vivo)0.5% methylcellulose: 30 mg/mL
    SynonymsSYR-322; SYR322; SYR 322; Alogliptin; Brand name: Nesina, Kazano, Oseni 

    Chemical Name: (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile

    InChi Key: ZSBOMTDTBDDKMP-OAHLLOKOSA-N

    InChi Code: 1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1

    SMILES Code: n1(c(=O)cc(n(c1=O)Cc1c(cccc1)C#N)N1C[C@@H](CCC1)N)C           


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: Alogliptin (also known as SYR-322) is a novel, potent, orally bioavailable, and selective inhibitor of DPP-4 (serine protease dipeptidyl peptidase IV) with IC50 value of 2.6 nM, it exhibits greater than 10,000-fold selectivity for DPP-4 over the closely related DPP-8 and DPP-9. It is an anti-diabetic drug marketed in Japan since 2010; and in 2013, the FDA approved the drug in three formulations: as a stand-alone with the brand-name Nesina, combined with metformin using the name Kazano, and when combined with pioglitazone as Oseni. Like other medications for the treatment of Type 2 diabetes, alogliptin does not decrease the risk of heart attack and stroke. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone. 


    Kinase Assay: Alogliptin (also known as SYR-322) is a novel, potent, orally bioavailable, and selective inhibitor of DPP-4 (serine protease dipeptidyl peptidase IV) with IC50 value of 2.6 nM, it exhibits greater than 10,000-fold selectivity for DPP-4 over the closely related DPP-8 and DPP-9. Alogliptin is not an inhibitor of CYP-450 enzymes and does not block the hERG channel at concentrations up to 30 μM.

    In VivoAlogliptin(SYR-322) produces dose-dependent improvements in glucose tolerance and increases plasma insulin levels in female Wistar fatty rats. Acute administration of alogliptin results in a significant decrease in plasma DPP-4 activity, and increases plasma active GLP-1. Alogliptin improves glucose tolerance at a dose of 0.3 mg/kg and higher, with a dose-dependent increase in plasma IRI, suggesting that improved glucose tolerance results from the ability of alogliptin to enhance insulin secretion.
    Animal modelN-STZ-1.5 rats
    Formulation & DosageDissolved in 0.5% methylcellulose; 0.1, 0.3, 1 or 3 mg/kg; p.o. administration
    ReferencesJ Med Chem. 2007 May 17;50(10):2297-300; Life Sci. 2009 Jul 17;85(3-4):122-6


    These protocols are for reference only. InvivoChem does not independently validate these methods.

     

    Alogliptin

     

    Alogliptin

     
    Alogliptin
    J Med Chem. 2007 May 17;50(10):2297-300.

    Effect of alogliptin on plasma DPP-IV activity (A) and plasma active GLP-1 ...

    Life Sci. 2009 Jul 17;85(3-4):122-6.

    Effects of alogliptin on plasma glucose (A), plasma IRI (B) baseline ...

    Life Sci. 2009 Jul 17;85(3-4):122-6.
     

    Effects of alogliptin on plasma glucose (A), baseline (0 min) adjusted ...

    Life Sci. 2009 Jul 17;85(3-4):122-6.


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Email: sales@invivochem.com
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved